Company intelligence / Profile preview

Check-Cap Ltd.

Ownership: Public · CHEK
Employees: ~85
Development stage: Commercial

Overview

Check-Cap has initiated a U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following FDA approval. The first patients have ingested C-Scan at the New York University School of Medicine. The company has also enrolled patients in a multi-center study in support of its CE Mark submission[4].

Therapeutic areas: Oncology
Modalities: Medical device (capsule-based screening technology)
Industry: Medical Imaging

Drug pipeline

1 asset

C-Scan

Commercial

Indications: Colorectal cancer screening

Partnerships

GE Healthcare (investor)[4]

Financials

Market cap: $10.9M
Total revenue: $0
Enterprise value: $10.8M

Beyond the preview

Go deeper on Check-Cap Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Check-Cap Ltd..

Explore the full profile